Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Next Previous
Trial Profile

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Renal failure; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms BEACON
  • Sponsors Reata Pharmaceuticals

    • Most Recent Events

    • 11 Oct 2019 According to a Reata Pharmaceuticals media release, results of a post hoc analysis of this trial will be presented at the American Society of Nephrology Kidney Week 2019 Annual Meeting. Abstract is avialable on he conference website at https://www.asn-online.org/education/kidneyweek/archives/.
    • 18 Jan 2018 Results published in a Reata Pharmaceuticals media release
    • 14 Nov 2016 According to a Reata Pharmaceuticals Media Release, based on the data of an analysis assessing risk factors and its risk mitigation strategy for managing acute fluid retention of this trial, FDA approved the Phase 2 program in PAH (LARIAT)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top